Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 29
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Perspective Therapeutics Inc
CATX
AMEX
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$1.20
-0.055
-4.4%
Últ. Act.: Oct 29, 1:26 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Perspective Therapeutics Analyst Price Targets - Benzinga
Perspective Therapeutics Analyst Price Targets
Wall Street analyst price targets and consensus rating for Perspective Therapeutics (CATX).
Analyst Ratings News
PRO
RBC Capital Downgrades Perspective Therapeutics to Sector Perform, Lowers Price Target to $4
RBC Capital analyst Leonid Timashev downgrades Perspective Therapeutics (AMEX:CATX) from Outperform to Sector Perform and lowers the price target from $14 to $4.
Benzinga Newsdesk
PRO
BTIG Reiterates Buy on Perspective Therapeutics, Maintains $14 Price Target
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maintains $14 price target.
Benzinga Newsdesk
This $3 Biotech Could Be Worth $11.45, Analyst Says
William Blair initiates Perspective Therapeutics (NYSE: CATX) at Outperform, citing its strong radiopharmaceutical platform.
Vandana Singh
PRO
William Blair Initiates Coverage On Perspective Therapeutics with Outperform Rating
William Blair analyst Andy Hsieh initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating.
Benzinga Newsdesk
PRO
Wedbush Reiterates Outperform on Perspective Therapeutics, Maintains $11 Price Target
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperform and maintains $11 price target.
Benzinga Newsdesk
PRO
BMO Capital Initiates Coverage On Perspective Therapeutics with Outperform Rating, Announces Price Target of $11
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Benzinga Newsdesk
Crear lista de seguimiento
GRATIS: Haz un seguimiento de acciones y criptomonedas con las mejores alertas de Internet
Haz clic para comenzar
People Also Watch
AbbVie Inc
NYSE:ABBV
$288.29
0.8%
Amgen Inc
NASDAQ:AMGN
$458.07
1.38%
Gilead Sciences Inc
NASDAQ:GILD
$161.02
1.14%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
$537.18
1.41%
Moderna Inc
NASDAQ:MRNA
$218.3
1.93%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
$813.66
0.05%
Natera Inc
NASDAQ:NTRA
$429.6
1.22%
argenx SE
NASDAQ:ARGX
$899.27
0.84%
BeOne Medicines Ltd
NASDAQ:ONC
$370.79
-0.69%
Revolution Medicines Inc
NASDAQ:RVMD
$189.34
0.33%
Muestra todas las empresas relacionadas con 10
